{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"0.77"},{"groupId":"OG001","spread":"0.20","value":"0.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.21","value":"0.03"},{"groupId":"OG001","spread":"0.19","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.23","value":"-0.10"},{"groupId":"OG001","spread":"0.41","value":"-0.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.21","value":"0.01"},{"groupId":"OG001","spread":"0.20","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"0.01"},{"groupId":"OG001","spread":"0.20","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"0.06"},{"groupId":"OG001","spread":"0.18","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.00","value":"-0.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"comment":"Standard deviation is non-evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"0.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (\"confined to bed\"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under \"CFB at Follow-up Month 2\" and \"CFB at Follow-up Month 4\" categories.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4 and 14","title":"CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}